Hutchison China MediTech’s name change to HUTCHMED unifies its corporate identity and better reflect its increasing global focus. FY20 results and pipeline update shows product and clinical momentum is maintained.
05 Mar 2021
Transitioning to a global oncology player
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Transitioning to a global oncology player
HUTCHMED (China) Limited (HCM:LON) | 264 6.6 0.9% | Mkt Cap: 2,302m
- Published:
05 Mar 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
Hutchison China MediTech’s name change to HUTCHMED unifies its corporate identity and better reflect its increasing global focus. FY20 results and pipeline update shows product and clinical momentum is maintained.